The federal framework — 18 U.S.C. § 1347 and the penalty escalation
Federal healthcare fraud under 18 U.S.C. § 1347 is a felony with a 10-year per-count maximum that escalates to 20 years if the scheme causes serious bodily injury and life imprisonment if it results in death. The penalty structure makes § 1347 one of the highest-exposure white-collar offenses in the federal code.
- Knowingly and willfully — the mens rea
- Section 1347 requires that the defendant act "knowingly and willfully." Knowledge means the defendant was aware of the relevant facts of the scheme. Willfulness in fraud prosecutions generally requires that the defendant acted with knowledge that the conduct was unlawful — although the precise contour of willfulness varies by circuit and by statute. The 2010 amendments to § 1347(b) clarified that a person need not have actual knowledge of § 1347 or specific intent to violate it. The willfulness inquiry usually focuses on whether the defendant knew the conduct was wrongful in some general sense, not on legal-encyclopedia knowledge.
- A scheme or artifice — actus reus
- The defendant must have executed or attempted to execute a "scheme or artifice." The terms are interpreted broadly — they reach any plan, design, or strategy involving the use of fraudulent or deceptive means to achieve an unlawful objective. A single submission of a false claim can satisfy the actus reus if it is part of a broader scheme; the scheme need not have succeeded. Each separate execution of the scheme — typically each false claim or each kickback payment — can be charged as a separate count, producing indictments with dozens or hundreds of counts and corresponding stacked-statutory-maximum exposure.
- To defraud OR to obtain money or property through false pretenses
- Section 1347 prohibits two distinct types of schemes — (1) schemes to defraud a health care benefit program, and (2) schemes to obtain money or property from a health care benefit program by false or fraudulent pretenses, representations, or promises. The two clauses overlap substantially but are not coextensive. The first prong reaches schemes that deprive the program of money, property, or honest services even if the means did not involve specific affirmative misrepresentations. The second prong is tied to false statements and is closer to traditional false-pretenses fraud.
- Penalty escalation — 10/20/Life
- The base maximum is 10 years per count plus a fine under 18 U.S.C. § 3571 (typically $250,000 for individuals, $500,000 for organizations, or twice the gain or loss). If the violation results in "serious bodily injury" as defined by 18 U.S.C. § 1365(h)(3), the maximum increases to 20 years. If it results in death, the maximum is life imprisonment. These enhancement provisions have produced significant prosecutions in pill-mill cases involving overdoses and in surgical or medical-device fraud cases involving patient harm. The death-results enhancement is causation-driven and creates parallel issues to felony-murder liability — proximate cause, intervening factors, and substantial-step analysis all come into play.
The federal architecture for healthcare fraud is layered. Section 1347 sits at the center — a substantive offense statute with a 10/20/life escalation structure that places it among the highest-exposure federal economic-crime provisions. Around it cluster a series of companion statutes designed to capture every layer of conduct: 18 U.S.C. § 1349 for conspiracy to commit healthcare fraud (with the same statutory maximums as the substantive offense, no overt-act requirement under the post-Salinas conspiracy framework); 42 U.S.C. § 1320a-7b for the Anti-Kickback Statute prohibition on remuneration in exchange for federal-program referrals; 18 U.S.C. § 1035 for false statements relating to healthcare matters; 42 U.S.C. § 1395nn (Stark Law) for self-referral arrangements; 18 U.S.C. §§ 1956 and 1957 for money laundering of proceeds; and 31 U.S.C. § 3729 for civil False Claims Act recovery. A typical Strike Force indictment combines four or five of these in overlapping counts.
The penalty structure is exceptional. The 10-year per-count maximum is itself substantial; the 20-year enhancement for serious bodily injury and the life-imprisonment enhancement for death make § 1347 one of the few non-violent federal offenses with potential life exposure. These enhancements have driven substantial pre-trial detention orders under 18 U.S.C. § 3142 in cases involving -overdose deaths tied to pill-mill prosecutions, and they shape plea-negotiation posture significantly. Under the U.S. Sentencing Guidelines, however, the Guidelines range is loss-driven through § 2B1.1 — actual sentence calculations frequently produce ranges that fall far below the statutory maximums for first offenders without bodily-injury enhancements, with significant variance based on the contested loss-amount figure.
Elements, scheme structure, and the scope of "health care benefit program"
Section 1347 reaches any "health care benefit program" as broadly defined by 18 U.S.C. § 24(b) — Medicare, Medicaid, TRICARE, ERISA plans, and private insurance. The breadth of § 24(b) is why § 1347 prosecutions sweep across providers, suppliers, billing companies, marketers, and beneficiaries.
The reach of § 1347 is driven by the definition of "health care benefit program" in 18 U.S.C. § 24(b). The statute defines the term as "any public or private plan or contract, affecting commerce, under which any medical benefit, item, or service is provided to any individual, including any individual or entity who is providing a medical benefit, item, or service for which payment may be made under the plan or contract." Two features of this definition expand the statute's footprint enormously. First, the program may be public OR private — § 1347 reaches private insurance fraud as readily as Medicare or Medicaid fraud. Second, the definition includes any individual or entity providing a benefit for which payment may be made — meaning providers, suppliers, billing companies, marketers, and even patients themselves can fall within the statute.
The factual patterns recurring in DOJ Healthcare Fraud Strike Force prosecutions cluster around several scheme types. Durable medical equipment (DME) fraud — billing for power wheelchairs, back braces, orthotics, or genetic-testing kits that were medically unnecessary, never provided, or upcoded — has been the largest single category of Strike Force indictments since 2018. Home health agency fraud — billing for nursing visits that were not provided, were not medically necessary, or were performed by unlicensed personnel — is a long-running category, particularly in the Eastern and Northern Districts of Texas. Laboratory fraud — billing for unnecessary or duplicative tests, often tied to genetic testing or cardiovascular panels, and routinely involving marketer kickbacks — became a major focus during and after the COVID-19 emergency, with massive parallel investigations into "labs of convenience." Pharmacy and prescription-drug fraud — compound pharmacy markups, billing for non-FDA-approved compounds, dispensing without legitimate prescriptions, and pill-mill operations — generates both § 1347 and 21 U.S.C. § 841 controlled-substance counts. Telehealth and "patient brokering" schemes proliferated during COVID, producing a wave of post-2022 Strike Force indictments that continue working through the federal courts.
Identifying the precise scheme structure early matters for the defense. Each scheme architecture suggests a different defense focus. A DME case may turn on whether the defendant signed the certifications of medical necessity or relied on the assessments of contracted physicians; a home health case may turn on whether the agency leadership was aware of the underlying patient-eligibility falsifications by field staff; a laboratory case may turn on whether the orderingphysicians had a documented basis for the tests; a pharmacy case may turn on the compounding pharmacist's understanding of the medical-necessity documentation. The defense team's first weeks of work are spent reconstructing the actual operational flow of the alleged scheme — who decided what, who knew what, who signed what, and who relied on whom — to identify where the prosecution's mens-rea proof is thinnest.
Federal venue and jurisdiction analysis is independently important. Under 18 U.S.C. § 3237, venue lies wherever any part of the offense was committed — typically multiple districts, because billing occurs in one location, patient services occur in another, and the program's payment processing occurs in a third. The government routinely selects venue strategically for trial-tactical advantages, and the defense routinely challenges venue selection where the connection to the chosen district is attenuated. Texas defendants charged in the Eastern District (Tyler, Sherman, Plano) or Northern District (Dallas, Fort Worth) face Strike Force units with deep institutional expertise — the Dallas Strike Force has run continuously since 2018 and has indicted billions of dollars of alleged fraud.
The Anti-Kickback Statute under 42 U.S.C. § 1320a-7b as a parallel theory
The federal Anti-Kickback Statute prohibits any payment or remuneration in exchange for federal-program referrals. AKS violations are felonies (up to 10 years) and routinely accompany § 1347 indictments — the "one purpose" rule means partial unlawful intent is sufficient even if legitimate purposes also existed.
The federal Anti-Kickback Statute at 42 U.S.C. § 1320a-7b(b) is the second major weapon in the DOJ healthcare-fraud arsenal. The statute prohibits any person from "knowingly and willfully" offering, paying, soliciting, or receiving "any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind" — to induce referrals for items or services for which payment may be made in whole or in part under a federal healthcare program. A violation is a felony with a 10-year per-count maximum, a fine under 18 U.S.C. § 3571, and — critically — mandatory exclusion from participation in all federal healthcare programs under 42 U.S.C. § 1320a-7(a). For a provider, mandatory exclusion is often more career-destroying than the criminal penalty itself.
The doctrine that makes the AKS particularly dangerous to defendants is the "one purpose" rule, articulated most prominently in United States v. Greber, 760 F.2d 68 (3d Cir. 1985), and adopted across virtually every other federal circuit. Under Greber, if even one purpose of the payment was to induce referrals, the statute is violated — even if other legitimate purposes (rental of office space, consulting services, etc.) also existed. The rule means that compensation arrangements that mix legitimate purposes with even a small inducement component can produce criminal liability, and it places enormous emphasis on contemporaneous documentation of the legitimate purposes of any provider compensation.
The AKS has an extensive set of statutory safe harbors at 42 C.F.R. § 1001.952, designed to protect legitimate business arrangements that might otherwise raise AKS concerns. The most heavily used safe harbors include bona fide employment compensation; personal services and management contracts (with six specific element requirements — written agreement, signed by the parties, specifies all services, term of at least one year, specifies aggregate compensation in advance, and aggregate compensation reflects fair market value not exceeding what is necessary); investment interests in qualifying entities; group purchasing organizations; and rental of office space or equipment. Safe-harbor compliance is a complete defense to AKS liability — but the safe harbors require strict compliance with every element. A safe-harbor analysis is therefore a central component of any AKS defense theory.
The intersection between AKS and § 1347 is where many Strike Force prosecutions live. The standard charging pattern is: (1) AKS counts under § 1320a-7b for the kickback payments themselves; (2) § 1347 counts for the resulting claims submitted to the federal program (the kickback-induced referrals produce false or fraudulent claims, because the claims violate program rules); (3) § 1349 conspiracy counts wrapping the entire enterprise; (4) money-laundering counts under §§ 1956 and 1957 for the movement of proceeds; and frequently (5) FCA civil parallels under § 3729. The defense must address each prong — and even successful defense of the AKS theory does not necessarily defeat the § 1347 theory or vice versa, although they typically rise and fall together.
The False Claims Act and qui tam parallel exposure
The civil False Claims Act runs alongside virtually every federal healthcare fraud prosecution — imposing treble damages plus per-claim penalties currently $13,946-$27,894. Qui tam relators (often former employees) file under seal and share 15-30% of any recovery, generating parallel civil exposure that often exceeds the criminal sentence.
The False Claims Act at 31 U.S.C. §§ 3729-3733 is the principal civil tool the federal government uses against healthcare fraud — and it operates as a parallel proceeding alongside virtually every criminal § 1347 prosecution. Civil liability under the FCA arises when a person (a) knowingly presents or causes to be presented a false or fraudulent claim for payment to the government, (b) knowingly makes, uses, or causes to be made or used a false record or statement material to a false claim, (c) conspires to commit a violation, or (d) commits other specified acts. The "knowingly" standard under § 3729(b) reaches actual knowledge, deliberate ignorance, and reckless disregard — broader than the criminal "knowing and willful" standard under § 1347.
Civil damages under the FCA are draconian. The statute imposes treble damages (three times the actual damages the government sustained), plus per-claim statutory penalties currently between $13,946 and $27,894 per claim (figures adjusted annually for inflation under the Federal Civil Penalties Inflation Adjustment Act and codified at 28 C.F.R. § 85.5). In a healthcare fraud case involving thousands of allegedly false claims — easily reached in any sustained billing scheme — the per-claim penalties alone routinely exceed the actual loss to the program. A single mid-size DME or laboratory case can generate civil liability in the tens or hundreds of millions of dollars even where the criminal sentence is modest by federal standards.
The qui tam mechanism at § 3730(b) is what brings most healthcare FCA cases into being. A private "relator" — often a former employee, business partner, or industry insider — files a sealed complaint on the government's behalf and gives the government 60 days (typically extended for years in practice) to investigate before deciding whether to intervene. If the government intervenes, the relator may share 15-25% of any recovery; if the government declines and the relator pursues the case independently and prevails, the relator may share 25-30%. Qui tam suits supply the government with detailed inside information and a head start that often makes the difference between a successful prosecution and an uninvestigated allegation. The government routinely opens criminal investigations in parallel with sealed qui tam complaints, with the civil and criminal teams sharing information freely.
The materiality and falsity standards under the FCA have been refined significantly since 2016. Universal Health Services v. United States ex rel. Escobar, 579 U.S. 176 (2016), recognized that submitting a claim while violating an underlying statutory, regulatory, or contractual requirement can be a false claim even without an express false statement — the "implied false certification" theory — but the violation must be material to the government's payment decision. The Court emphasized a "rigorous" materiality standard. United States ex rel. Schutte v. SuperValu, 598 U.S. 739 (2023), addressed the scienter standard, rejecting an objective-reasonableness defense and holding that the defendant's subjective belief about the falsity of a claim matters. These decisions cut in both directions — Escobar expanded the theories available to relators and the government, while SuperValu requires close attention to what the defendant actually believed at the time. Defense strategy in parallel FCA cases necessarily integrates with criminal-case strategy, because admissions and evidence in either proceeding can carry into the other.
Defense strategies overview
Federal healthcare fraud defense strategies cluster around mens-rea attack (intent, willfulness, knowledge of unauthorized conduct), loss-amount challenges at sentencing, AKS safe-harbor compliance, FCA materiality contests, and aggressive Brady/Giglio + qui tam relator impeachment.
Defending a federal healthcare fraud case is a multi-front effort that must integrate criminal, civil FCA, administrative exclusion, and licensing defense into a single coherent strategy. The criminal defense team typically begins with mens-rea analysis — what the government has to prove the defendant subjectively knew. Section 1347 requires "knowing and willful" execution of the scheme. The AKS requires the same. The FCA requires "knowing" submission of false claims (with the relaxed civil standard). After Ruan v. United States, 597 U.S. 450 (2022), in cases involving controlled-substance prescriptions, the government must prove the defendant subjectively knew the prescription was unauthorized. Each of these mens-rea elements is a potential defense focal point.
Good-faith reliance defenses are central. A physician who relied on the medical-necessity determinations of treating physicians; a pharmacy that relied on the prescriptions of authorized prescribers; a billing company that relied on the coding decisions of physician-certified personnel — each of these is a potential good-faith argument. Federal courts have generally recognized advice-of-counsel as a defense to willfulness in healthcare fraud cases, though the elements are demanding (full disclosure of all material facts to counsel, good-faith reliance on the resulting advice). Documented compliance programs, internal audit findings the defendant addressed, and consultation with healthcare counsel can all support good-faith arguments. The defense file-building work on these defenses begins in the first 30-60 days of representation.
Loss-amount challenges at sentencing are quantitatively the highest-impact area for defense work in healthcare fraud cases. Under U.S.S.G. § 2B1.1, the loss table can add up to 30 offense levels to the base level, and the difference between a defense-favorable loss-amount figure and a government-favorable one can mean a decade of difference in sentencing exposure. The government often uses statistical extrapolation methodologies — sample audit results scaled to total claims volume — to compute loss; the defense routinely challenges those methodologies, the sample selection, and the assumptions underlying the extrapolation. The Guidelines distinguish intended loss from actual loss and use the greater figure; United States v. Banks, 55 F.4th 246 (3d Cir. 2022), tightened the intended-loss analysis after the Supreme Court's Kisor framework limited deference to Guidelines commentary that conflicts with the text. These technical sentencing issues regularly produce litigation worth millions of dollars of effective sentence reduction.
Cooperation and 5K1.1 substantial assistance is a strategic consideration in cases where the defendant has insider information about co-conspirators or industry practices. Early cooperation — particularly cooperation against more culpable principals in the scheme — can produce substantial sentence reductions under U.S.S.G. § 5K1.1. The cooperation decision is freighted with consequences (loss of certain trial defenses, exposure to professional discipline, civil and criminal exposure of close colleagues) and requires careful evaluation early in the case. Brady/Giglio discovery development on qui tam relator credibility is another important defense lever — relators often have financial incentives that affect their reliability, and their testimony or evidence may be undermined by impeachment material that defense investigation produces.
The Ruan knowledge standard for pill-mill prosecutions
Ruan v. United States, 597 U.S. 450 (2022), restructured the defense landscape for physicians charged under 21 U.S.C. § 841 with prescribing controlled substances outside the usual course of professional practice. The government must now prove the defendant subjectively knew the prescription was unauthorized — a substantial expansion of good-faith defenses.
The Supreme Court's decision in Ruan v. United States, 597 U.S. 450 (2022), restructured the federal defense landscape for physicians and other practitioners charged with prescribing controlled substances outside the usual course of professional practice. Before Ruan, several circuits applied an objective "reasonable-physician" standard to 21 U.S.C. § 841(a) and § 843 prosecutions — once the government proved that the prescription was not for a legitimate medical purpose, the defendant could be convicted regardless of his subjective belief about the prescription's authorization. Ruan rejected that approach unanimously.
The Court held that once a defendant produces evidence that his prescriptions were authorized — that is, that they were issued for a legitimate medical purpose in the usual course of professional practice — the government must prove beyond a reasonable doubt that the defendant knew or intended his conduct was unauthorized. The mens rea inquiry is subjective, not objective. A physician who genuinely believed he was practicing medicine appropriately, even if a peer-review panel or expert witness later concludes the practice fell below professional standards, is not guilty of a § 841 violation absent proof of subjective knowledge that the conduct was unauthorized.
The post-Ruan defense landscape in pill-mill prosecutions has been substantially reshaped. Defense expert testimony on standard medical practice — historically used to challenge the government's evidence that the prescriptions deviated from professional norms — now plays a more important role as evidence of the defendant's subjective good-faith belief that he was practicing within the standard of care. Documentation of the defendant's clinical reasoning, treatment plans, follow-up protocols, monitoring of patient outcomes, and consultations with colleagues becomes critical evidence of the subjective good-faith state. The government must now demonstrate not just that the prescriptions were objectively unauthorized but that the defendant himself knew or intended that they were.
Practical effect on charging and plea-negotiation posture is significant. DOJ Healthcare Fraud Strike Force units have continued to bring pill-mill prosecutions post-Ruan, but the threshold for credible charging has risen — the government must now develop subjective-knowledge evidence (informant testimony from staff, surveillance of office practices, financial records showing patterns consistent with intentional drug-diversion rather than ordinary medical practice) rather than relying on expert testimony about objective unreasonableness. Defense plea-negotiation leverage has correspondingly increased. The most consequential post-Ruan litigation in the Northern and Eastern Districts of Texas has involved how juries are instructed on the subjective-knowledge element and what evidence the government can use to prove it, including circumstantial inferences from atypical practice patterns. Practitioners charged with controlled-substance offenses arising out of healthcare-fraud investigations should ensure their defense counsel is current on Ruan and its progeny — the framework has been one of the most significant pro-defense developments in federal criminal law in the last decade.
Local DFW practice — Strike Force, HEAT, FBI and HHS-OIG coordination
The Northern District of Texas Healthcare Fraud Strike Force has run continuously since 2018, indicting billions of dollars of alleged fraud in coordination with the FBI Healthcare Fraud Program and HHS-OIG. Common DFW schemes include DME, home health, laboratory testing, hospice, and pharmacy compounding.
The DOJ Healthcare Fraud Strike Force operating out of the Northern District of Texas — based primarily in Dallas with extensions into the Eastern District — is one of the most aggressive units in the country, having indicted multiple billions of dollars in alleged healthcare fraud since its 2018 inception. The Strike Force draws on prosecutors from the DOJ Criminal Division Fraud Section in Washington, paired with Assistant U.S. Attorneys from the Northern and Eastern Districts of Texas, and works in tight coordination with FBI Special Agents from the Healthcare Fraud Program, Investigators from the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG), and analysts from the Centers for Medicare & Medicaid Services (CMS). The unit's docket reflects the broader DOJ HEAT (Healthcare Fraud Prevention and Enforcement Action Team) priorities — the largest single category being DME fraud (power wheelchairs, back braces, orthotic devices, urinary catheters), followed by home health agency fraud, laboratory testing fraud, hospice fraud, and pharmacy/compounding fraud.
The investigative tools used in DFW healthcare fraud cases are extensive. Medicare/Medicaid claims data analytics — running pattern-recognition algorithms across the universe of billed claims to identify outlier providers — supplies most initial referrals. CMS's Fraud Prevention System and the Healthcare Fraud Prevention Partnership combine government and private-insurer claim data to identify cross-payer scheme indicators. Once a target is identified, investigators use undercover beneficiaries posing as patients to capture provider conduct, surveillance of office practices, interviews with current and former employees, grand jury subpoenas to vendors and suppliers, and search warrants on offices and electronic records. Parallel qui tam relator complaints — frequently filed by former employees or competitors — provide insider information that complements the data-driven investigative approach. Most cases originate with either a relator or a data-analytics flag, with full investigative development running 18-36 months before indictment.
The common scheme architectures in DFW prosecutions are recognizable. DME schemes typically involve telemarketing-driven patient recruitment, with brace or wheelchair orders generated by call centers and then funneled through telemedicine-physician sign-offs based on minimal medical evaluation; the kickback structure pays the telemarketers, the call centers, and the sign-off physicians. Home health agency schemes involve falsified eligibility certifications (the patient was not homebound or did not require skilled nursing), billing for visits not provided, and unlicensed personnel performing nominally skilled services. Laboratory testing schemes have evolved through several waves — first cardiovascular and pharmacogenetic panels, then COVID-19-driven respiratory pathogen testing, more recently cancer-genetic and toxicology testing — with the common thread being marketer kickbacks (typically paid as "marketing fees" or "consulting payments") to physicians or marketing intermediaries to generate medically unnecessary referrals. Hospice fraud involves admitting patients who do not meet the six-month-life-expectancy criterion, often coupled with kickbacks to referring nursing facilities or physicians. Pharmacy compounding fraud involves billing for compounded medications that were either medically unnecessary, never properly compounded, or marked up to extraordinary levels relative to their constituent costs.
Local DFW counsel familiar with the Strike Force's operational rhythms, the U.S. Attorneys' Offices' charging tendencies, and the federal judges of the Northern and Eastern Districts is an asset throughout the case. The judges of the Northern District (sitting primarily in Dallas, Fort Worth, and Amarillo divisions) and the Eastern District (sitting primarily in Sherman, Plano, Tyler, and Texarkana divisions) have well-developed approaches to healthcare fraud sentencing — variances from the Guidelines are common, departures from the loss-amount calculations are well-litigated, and the judges expect detailed factual development on the mens rea and loss-amount issues. Pretrial motion practice, expert development on standard of medical care, and the scheduling of plea negotiations against the case calendar are all matters where local familiarity matters.
When to retain counsel — investigation, target, subject, witness
The right time to retain federal healthcare fraud counsel is the day you receive a grand jury subpoena, a target letter, an HHS-OIG agent interview request, or a civil investigative demand under the FCA. Counsel involved early protects privilege, manages the records, and preserves both criminal and licensing options.
The earliest moment to retain federal healthcare fraud counsel is at the first sign of government interest — a grand jury subpoena to the practice, a target letter from a U.S. Attorney's Office or DOJ Criminal Division, an HHS-OIG Special Agent request for an interview, a Civil Investigative Demand (CID) under the False Claims Act, or a search warrant executed at an office or home. Each of these signals indicates an active investigation and creates immediate decision points where wrong choices can foreclose options that experienced counsel would otherwise preserve. The cost of retaining counsel at the subpoena or target-letter stage is substantially less than the cost (financial and otherwise) of retaining counsel mid-grand-jury or post-indictment, when the case has already taken shape on the government's terms.
The government uses three primary status categories during the investigation phase: witness, subject, and target. A witness is not believed to have committed any wrongdoing; a subject is a person whose conduct is within the scope of the investigation but who is not currently the focus of criminal prosecution; a target is a person against whom the prosecutor has substantial evidence linking them to the commission of a crime and who is a putative defendant. Status can change during the investigation — a witness today may become a subject next month and a target the month after. Government interactions with people in each category are governed by different sets of rules, and conduct that is appropriate for one category (cooperative interview, voluntary document production) is risky for another. Counsel's job is to evaluate the client's probable status, manage the document production, manage interview requests, and preserve future options.
Records management is one of the most consequential early-investigation tasks. Healthcare practices and businesses receiving grand jury subpoenas, HHS-OIG document requests, or CIDs must implement litigation holds to preserve responsive records, identify and segregate privileged documents (attorney-client communications, work product), and conduct careful privilege reviews before producing documents. Healthcare records are particularly complex — they include patient medical records covered by HIPAA, claims data covered by various federal privacy rules, employee personnel records, billing system data, and financial records — and a poorly executed privilege review can result in inadvertent waiver of privilege or production of documents that materially harm the client. Vendor selection for e-discovery, the timing and structure of internal investigations, and the use of internal-investigation reports all require careful counsel-led decision-making.
Parallel proceedings management is another critical area. Healthcare practitioners under federal investigation often face simultaneous proceedings before state medical boards, the Texas State Board of Pharmacy, the DEA (administrative proceedings on DEA registration), HHS-OIG (administrative exclusion proceedings), CMS (revocation of Medicare billing privileges), and private payors (audit recoupments, network termination). The criminal case may move slowly through grand jury and indictment, while the licensing and administrative proceedings move quickly with significant immediate consequences (suspended billing privileges, restricted licenses, exclusion from federal programs). Coordinating the defense strategy across all of these proceedings — preserving Fifth Amendment rights where possible while still defending the licensing and administrative tracks — is one of the most strategically delicate areas of federal healthcare-fraud practice. The defense team typically includes white-collar criminal counsel, healthcare-regulatory counsel, licensing-defense counsel, and (where qui tam exposure exists) FCA-defense counsel, with the criminal defense lead coordinating the overall strategy.
